GlassScriptPhysician profile
Katelyn Vignola
NPI 1336616044
$7,099.01
in general payments reported to CMS, 2019-2025
31 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,553 · 2022: $1,158 · 2023: $1,247 · 2024: $2,968 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,962 · Consulting Fee: $1,330 · Education: $75.74 · Travel and Lodging: $21.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,961.75 |
| Consulting Fee | $1,330.00 |
| Education | $75.74 |
| Travel and Lodging | $21.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,793.80 | 2021-2025 | Descovy |
| Viiv Healthcare Company | $841.71 | 2022-2025 | Cabenuva, Apretude, Dovato |
| Abbvie INC. | $807.38 | 2021-2024 | |
| Amgen INC. | $642.93 | 2021-2023 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $513.81 | 2021-2025 | Pifeltro, Delstrigo |
| Theratechnologies INC. | $238.21 | 2023-2024 | Egrifta, Trogarzo, Egrifta Sv |
| Janssen Biotech, INC. | $191.96 | 2022-2023 | Symtuza |
| Biohaven Pharmaceuticals, INC. | $186.30 | 2021 | |
| Glaxosmithkline, LLC. | $158.10 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.95 | 2022 | |
| Novo Nordisk INC | $89.77 | 2021-2024 | |
| Janssen Scientific Affairs, LLC | $74.13 | 2022-2023 | Symtuza |
| Astrazeneca Pharmaceuticals LP | $67.43 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.75 | 2022 | |
| Hologic Sales and Service, LLC | $39.96 | 2022-2024 | Aptima, Thinprep 2000 Processor |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $34.97 | 2022-2023 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.32 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.02 | 2021 | |
| Emd Serono, INC. | $26.56 | 2021 | |
| Abbott Laboratories | $24.75 | 2024 | Freestyle Libre 3 |
| Alnylam Pharmaceuticals INC. | $23.75 | 2021 | |
| Alkermes, INC. | $23.59 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.06 | 2021 | |
| Daiichi Sankyo INC. | $16.87 | 2021 | |
| Jazz Pharmaceuticals INC. | $14.53 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.46 | 2024 | Caplyta |
| Currax Pharmaceuticals LLC | $14.23 | 2021 | |
| Dexcom, INC. | $11.40 | 2021 | |
| Indivior INC. | $11.29 | 2021 | |
| Janssen Pharmaceuticals, INC | $10.74 | 2023 | |
| Clarus Therapeutics INC. | $6.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Vignola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.